A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAFV600 wild-type colorectal cancer.
Alexandros GeorgiouAdam StewartGeorgios VlachogiannisLisa PickardNicola ValeriDavid CunninghamSteven R WhittakerUdai BanerjiPublished in: Cellular oncology (Dordrecht) (2021)
Our findings suggest activation of the PI3K pathway as a mechanism of cetuximab resistance in KRAS/NRAS/BRAFV600 wild-type CRC.